ConductScience.org, home

Paper23722425

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Weiskopf K and 10 others. Science, 2013. Cited by 424 papers, by iCite.

Cite this record

ConductScience Library. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Papers, record 23722425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23722425

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.
PubMed
Journal
Science
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
424
iCite
Relative citation ratio, by iCite
9.71
iCite
Revised in PubMed
2024-06-10
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Weiskopf KKipp
2Ring AMAaron M
3Ho CCChia Chi M
4Volkmer JPJens-Peter
5Levin AMAron M
6Volkmer AKAnne Kathrin
7Ozkan EEngin
8Fernhoff NBNathaniel B
9van de Rijn MMatt
10Weissman ILIrving L
11Garcia KCK Christopher

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adjuvants, ImmunologicMajor topic
Antibodies, MonoclonalMajor topic
Antibodies, NeoplasmMajor topic
Antigens, DifferentiationMajor topic
CD47 AntigenMajor topic
NeoplasmsMajor topic
Receptors, ImmunologicMajor topic
Animals
Antibodies, Monoclonal, Murine-Derived
Cell Line, Tumor
Directed Molecular Evolution
Humans
Immunotherapy
Macrophage Activation
Mice
Phagocytosis
Rituximab

Source PubMed

Download CSV of topics

Grants12

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 GM007365NIGMS NIH HHSUnited StatesT32GM007365PubMed and NIHNIH RePORTER
F30CA168059NCI NIH HHSUnited StatesF30CA168059PubMed and NIHNIH RePORTER
F30DK094541NIDDK NIH HHSUnited StatesF30DK094541PubMed and NIHNIH RePORTER
F30 DK094541NIDDK NIH HHSUnited StatesF30DK094541PubMed and NIHNIH RePORTER
Howard Hughes Medical InstituteUnited StatesPubMedPubMed
R01 CA086017NCI NIH HHSUnited StatesR01CA086017PubMed and NIHNIH RePORTER
GM07365NIGMS NIH HHSUnited StatesT32GM007365PubMed and NIHNIH RePORTER
CA139490NCI NIH HHSUnited StatesP01CA139490PubMed and NIHNIH RePORTER
P01 CA139490NCI NIH HHSUnited StatesP01CA139490PubMed and NIHNIH RePORTER
F30 CA168059NCI NIH HHSUnited StatesF30CA168059PubMed and NIHNIH RePORTER
R01 CA177684NCI NIH HHSUnited StatesR01CA177684PubMed and NIHNIH RePORTER
R01 CA112270NCI NIH HHSUnited StatesR01CA112270PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in23743478Tumour immunology: cracking the combination.https://conductscience.org/library/papers/23743478PubMed
Comment in23812266Anticancer drugs: Cracking the combination.https://conductscience.org/library/papers/23812266PubMed
Comment in23828933Immunology. Making macrophages eat cancer.https://conductscience.org/library/papers/23828933PubMed

Download CSV of comments and corrections

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117369261The structure of the macrophage signal regulatory protein alpha (SIRPalpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors.J Biol Chem2007https://conductscience.org/library/papers/17369261PubMed
210572074Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47.Blood1999https://conductscience.org/library/papers/10572074PubMed
321376230Hallmarks of cancer: the next generation.Cell2011https://conductscience.org/library/papers/21376230PubMed
41717984Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.Proc Natl Acad Sci U S A1991https://conductscience.org/library/papers/1717984PubMed
522451919Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22451919PubMed
620813259Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.Cell2010https://conductscience.org/library/papers/20813259PubMed
716290005Single step protocol to purify recombinant proteins with low endotoxin contents.Protein Expr Purif2006https://conductscience.org/library/papers/16290005PubMed
823293079Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment.Blood2013https://conductscience.org/library/papers/23293079PubMed
920383002Features and development of Coot.Acta Crystallogr D Biol Crystallogr2010https://conductscience.org/library/papers/20383002PubMed
1019339720Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N Engl J Med2009https://conductscience.org/library/papers/19339720PubMed
1120124702PHENIX: a comprehensive Python-based system for macromolecular structure solution.Acta Crystallogr D Biol Crystallogr2010https://conductscience.org/library/papers/20124702PubMed
1219632179CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.Cell2009https://conductscience.org/library/papers/19632179PubMed
1322451913The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22451913PubMed
1419632178CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.Cell2009https://conductscience.org/library/papers/19632178PubMed
158596936Enhancement of antitumor immunity by CTLA-4 blockade.Science1996https://conductscience.org/library/papers/8596936PubMed
1618657508Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47.Mol Cell2008https://conductscience.org/library/papers/18657508PubMed
1721436454CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.Science2011https://conductscience.org/library/papers/21436454PubMed
1810856220Role of CD47 as a marker of self on red blood cells.Science2000https://conductscience.org/library/papers/10856220PubMed
1917982459Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells.Nat Immunol2007https://conductscience.org/library/papers/17982459PubMed
2017154393Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.Cancer2007https://conductscience.org/library/papers/17154393PubMed

See all 36 referencesDownload CSV of references

Cited by314

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 424 citations.

PMIDTitleJournalYearIn PapersSource
42946800Macrophage biology and immunoregulation in health and disease.Cell Mol Immunol2026https://conductscience.org/library/papers/42946800PubMed
42911425The pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiers.J Cancer Res Clin Oncol2026https://conductscience.org/library/papers/42911425PubMed
42686375GTPase RAB31 supports ANXA1-driven macrophage education through clathrin-mediated endocytosis to suppress antitumor immunity.J Immunother Cancer2026https://conductscience.org/library/papers/42686375PubMed
42608405High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma.Nat Commun2026https://conductscience.org/library/papers/42608405PubMed
42439665Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.Cells2026https://conductscience.org/library/papers/42439665PubMed
42384015Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.Br J Haematol2026https://conductscience.org/library/papers/42384015PubMed
42282282Macrophage-Targeted Single Walled Carbon Nanotubes Stimulate Phagocytosis via pH-dependent Drug Release.Nano Res2021https://conductscience.org/library/papers/42282282PubMed
42251359Engineering a PD-L1-sensing synthetic receptor for programmable macrophage response.J Biol Eng2026https://conductscience.org/library/papers/42251359PubMed
42183275Neutrophil efferocytosis in chronic inflammatory gastrointestinal diseases: mechanistic insights and therapeutic potential.Front Immunol2026https://conductscience.org/library/papers/42183275PubMed
41822520The SIRP family: from structural diversity and signaling mechanisms to implications in immune-related disease targeted therapeutics.Front Immunol2026https://conductscience.org/library/papers/41822520PubMed
41811295Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma.Expert Opin Investig Drugs2026https://conductscience.org/library/papers/41811295PubMed
41601654FACS-based genome-wide CRISPR screening platform identifies modulators of CD47.Front Immunol2025https://conductscience.org/library/papers/41601654PubMed
41556358PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41556358PubMed
41514569Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review.Cancers (Basel)2025https://conductscience.org/library/papers/41514569PubMed
41497624Engineering SIRPα conformational plasticity to reveal a cryptic pocket suitable for structure-based drug design.bioRxiv2025https://conductscience.org/library/papers/41497624PubMed
41444487Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy.Nat Commun2025https://conductscience.org/library/papers/41444487PubMed
41425717Research Progress of Drug Delivery Systems Consisting of Hydrogels Loaded with Extracellular Vesicles in Tumor Therapy.Oncol Res2025https://conductscience.org/library/papers/41425717PubMed
41423264TIPE2 deficiency enhances macrophage phagocytosis of tumor cells.J Immunother Cancer2025https://conductscience.org/library/papers/41423264PubMed
41360986Targeting phagocytosis checkpoints for cancer immunotherapy.Nat Rev Cancer2026https://conductscience.org/library/papers/41360986PubMed
41290673Bioorthogonal optimized virus immuno-nanomedicine (BOVIN).Nat Commun2025https://conductscience.org/library/papers/41290673PubMed

See all 314 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
PDB4KJY

Source PDB

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23722425

GET https://conductscience.org/api/papers/v1/23722425/references?page=2